In a study on 109 breast cancer patients, Huang et al. [46] observed that CD82-negative tumors had significantly lower 5-year disease-free survival compared to their CD82-positive counterparts; thus, showing that the reduction in CD82 expression is correlated with tumor recurrence. This evidence concerns the gene CD82 and breast cancer.